GLP-1RA, glucagon-like peptide-1 receptor agonist
Protecting GLP-1 Therapies, Protecting Business GLP-1 therapies are a breakthrough in chronic disease treatment
During 72 weeks of treatment, people taking tirzepatide at doses of 5, 10, or 15 mg lost an average of 15.0%, 19.5%, and 20.9%, respectively, compared with just 3.1% in people taking a placebo
The cards require that your insurance already covers the drug
But Eimer emphasized that the findings should not discourage appropriate use of GLP-1 drugs, which have become increasingly popular for treating diabetes, obesity, cardiovascular disease and sleep apnea
States that do opt to cover various weight loss treatments, including medications, nutrition programs and bariatric surgery, almost invariably deploy restrictive eligibility requirements around things like body mass indices and the presence of co-morbidities, along with the use of prior authorization and step edits